- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
The Top 5 Biosimilars Articles for the Week of March 26
The Center for Biosimilars® recaps the top 5 biosimilars articles for the week of March 26, 2018.
Transcript:
Hi, I'm Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of March 26.
Number 5: A new brief from Avalere Health says that a variety of policy options are available to the United States to create the necessary conditions for biosimilar competition.
Number 4: Mylan and Biocon's Lantus biosimilar has received marketing authorization in the European Union and in Australia.
Number 3: Intravitreal anti-vascular endothelial growth factor treatments, including bevacizumab, are not associated with an increased risk of adverse events.
Number 2: In a symposium at the 23rd annual conference of the National Comprehensive Cancer Network, 3 clinicians presented on the use of biosimilars in oncology.
Number 1: FDA Commissioner, Dr Scott Gottlieb, said this week that the FDA is working on numerous new policies to encourage biosimilar development.
Finally, last week, our e-newsletter asked whether you think Oregon's new drug price transparency law will help to control costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
